Please assess the completion status of the following clinical trial:

Trial Title: Effect of Empagliflozin on Liver Fat in Non-diabetic Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Potential study subjects will first be screened by transient elastography for the presence of hepatic steatosis (defined as a measurement of controlled attenuation parameter \[CAP\] \>= 248 db/M).~* They will be recruited into study if steatosis is \>= 5% as confirmed by MRI-PDFF~Exclusion Criteria:~* DM (defined as hemoglobin A1c \[HbA1c\] \>= 6.5% or fasting glucose \>= 7.0 mmol/L)~* alcohol intake \> 20g within past 2 years~* concurrent chronic liver diseases (including chronic viral hepatitis infection, autoimmune hepatitis, Wilson's disease, hemochromatosis, congestive hepatopathy, primary biliary cholangitis, primary sclerosing cholangitis, biliary tract obstruction)~* drug-induced liver disease~* usage of drugs that can lead to hepatic steatosis (e.g. steroids, amiodarone, valproate, methotrexate, tamoxifen)~* decompensated cirrhosis (including ascites, hepatic hydrothorax, variceal bleeding, hepatic encephalopathy, hepatorenal syndrome, hepatopulmonary syndrome)~* history of malignancy including HCC~* recreational substance abuse~* pregnancy~* contraindications to empagliflozin use (estimated glomerular filtration rate \[eGFR\] \<45mL/min/1.73m2 as measured by the MDRD equation, history of recurrent genitourinary tract infections, gangrene, or allergy)~* contraindications to MRI (e.g., claustrophobia, certain cardiac pacemakers, implanted medical devices with ferromagnetic properties).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Empagliflozin group (Type: EXPERIMENTAL): Empagliflozin 10mg daily for 52 weeks
- Placebo group (Type: PLACEBO_COMPARATOR): Placebo pills (identical in appearance to empagliflozin 10mg) daily for 52 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).